Big Tech and the National Health Service: Maintaining Equity in the AI Revolution

Where: Landmark Center at 401 Park Drive, 5th floor East, Boston, MA 02215

Speaker: Maxine Mackintosh, PhD, at the Alan Turing Institute and University College London

Date: October 21, 2019 at 4:00PM - 5:30PM

A day does not go by without a new framework for ethics in AI, particularly in health and social care. But when your health system is based on need versus ability to pay, yet the skills, computational power and often data lies in tech companies, from SMEs to multinationals, it can be difficult to see how a health system can digitize in an equitable and ethical manner. Maxine’s talk will share some examples of the learnings, attitudes and practical ways the UK has approached data stewardship, partnerships, “intangible assets" and transparency of health data organizations looking to work with the NHS. These examples will include learnings from DeepMind Health’s Independent Review Board, the use of consumer data in the UK for health research, and how the UK is approaching some of these discussions at a national, policy level.

Maxine Mackintosh is a PhD student at the Alan Turing Institute and University College London’s Institute of Health Informatics. Dr. Mackintosh is currently in Boston as a Winston Churchill Fellow. Her PhD involves using medical records to uncover early signs of dementia. Dr. Mackintosh is interested in how we might make better use of routinely collected data to inform our understanding of health and diseases. Prior to this, she completed a BSc in Biomedical Sciences (UCL) and an MSc in Health Policy, Planning and Financing (LSE & LSHTM).In addition, Maxine is the co-founder of One HealthTech — an international, volunteer-led, grassroots community which champions and supports underrepresented groups, particularly women, to be the future leaders in health innovation. Her professional work has led her to the Royal Society, Roche, L’Oreal, Department for International Development and NHS England. She is part of a number of communities and committees including the World Economic Forum’s Global Shapers, and the British Computer Society (Health Exec). Maxine also sat on DeepMind Health’s Independent Review Board and has a particular interest in fair and appropriate partnerships in the NHS.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.